Clinical Trials · NCT07739537

PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Not Yet RecruitingPhase 4Orforglipron (Investigational)
Phase
Phase 4
Recruitment status
Not Yet Recruiting
Sponsor
Massachusetts General Hospital
Enrollment
100
Start date
Oct 2026
Locations
See registry
Primary endpoint
Physiologic characterization by MMTT
View Orforglipron compound reference